前往化源商城

68643-23-2 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: SERCaMPGLuc-p1-antagonist
Protocol: PROTOCOL TABLES
SEQUENCE No. (1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Reagent; 5 uL; 1000 SH-SY5Y cells per wells
2; Time; 5 hour; 37C, 5% CO2
3; Compound; 23 nL; Control inhibitor / compound library
4; Time; 16 hour; 37C, 5% CO2
5; Reagent; 100 nM; Thapsigargin
6; Time; 4 hour; 37C, 5% CO2
7; Reagent; 1 uL; 0.5x coelenterazine
8; Detection; Luminescence; ViewLux imaging system

NOTES (numbers refer to sequence above)
1; SH-SY5Y human neuroblastoma cells stably expressing GLuc-SERCaMP (SH-SY5Y-GLuc-ASARTDL) cells were seeded in 1,536 well white tissue culture treated plates (Corning, Cat# 7464) in DMEM-high glucose-sodium pyruvate (ThermoFisher Scientific, Cat #10569) supplemented with 10% bovine growth serum (Hyclone), 10 U/ml penicillin (Gibco), 10 ug/ml streptomycin (Gibco), and 20 mM HEPES.
2; Assay plates were incubated for 5 hour at 37C in a humidified incubator containing 5% CO2.
3; qHTS libraries (23 nl, final concentrations of 1.53 uM, 7.67 uM, 38.3 uM) or controls (neutral control: DMSO, positive control: dantrolene) were added using a Kalypsis pin-tool Robotic System equipped with 1536 pinheads.
4; Cells were then incubated for 16 hours at 37C, 5% CO2.
5; Thapsigargin was added at 100 nM to deplete ER calcium stores.
6; Cells were incubated for 4 hour (37oC, 5% CO2)
7; Gaussia luciferase in the medium was measured by adding 1 ul of 0.5x coelenterazine (final concentration 0.07x) prepared in Gaussia Luciferase Glow Assay Buffer (Pierce), without addition of the Cell Lysis Buffer Reagent.
8; Luminescence was measured using a ViewLux high-432 throughput CCD imaging system (Perkin Elmer) equipped with clear filters. Compounds exhibiting inhibitory activity (defined as curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4, -3) were identified by normalizing plate-wise to corresponding intra-plate controls (neutral control = Tg only; positive control (100% inhibition) = DMSO vehicle) with percent activity derived using in-house software (https://tripod.nih.gov/curvefit). The same controls were also used for the calculation of the Z' factor, a measure of assay quality control, as previously described (Zhang et al., 1999). For the initial validation of activity in the SERCaMP assays, hits from the primary screen were assayed again at 11-concentrations (1.3 nM - 76.6 uM). SH-SY5Y-GLuc-SERCaMP cells were assayed for ER Ca2+ depletion as outlined above.

Reference:
1. Zhang, J.H., Chung, T.D., and Oldenburg, K.R. (1999). A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4, 67-73.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000259387 uMActivity at 0.0000710850 uMActivity at 0.0001271514 uMActivity at 0.0003024044 uMActivity at 0.0005030064 uMActivity at 0.0006524306 uMActivity at 0.00193 uMActivity at 0.00341 uMActivity at 0.00584 uMActivity at 0.010 uMActivity at 0.018 uMActivity at 0.052 uMActivity at 0.078 uMActivity at 0.156 uMActivity at 0.276 uMActivity at 0.478 uMActivity at 0.883 uMActivity at 1.507 uMActivity at 3.884 uMActivity at 7.354 uMActivity at 12.96 uMActivity at 21.63 uMActivity at 38.41 uMActivity at 76.33 uMActivity at 137.0 uMActivity at 204.0 uMCompound QC
Inhibitor1104.966488Complete curve; high efficacy-63.51170.6658-104.96640-1.10 0 0-97.13-85.6484-112.8671-97.13QC'd by Tocris
Inhibitor0.316259.327888Complete curve; high efficacy-6.50.81-84.7193-25.3915-1.10 0 0-83.9327-75.7429-81.922-83.9327QC'd by BIOMOL
Inhibitor3.162320.498785Complete curve; high efficacy-5.54.95490.4756-107.8212-87.3224-1.10 0 0-101.1849-96.9354-114.4343-101.1849QC'd by SIGMA
Inhibitor0.749266.151166Complete curve; partial efficacy-6.125410.8229-74.6135-8.4624-1.20 0 0 0 0 0 0 0 0 0 0-67.099-7.8787-22.7216-1.4525-29.6562-23.5194-8.332-25.0891-62.4832-68.6466-63.9027-67.099QC'd by Microsource
Inhibitor121.684566Complete curve; partial efficacy-64.95490.9699-77.7873-56.1028-1.20 0 0-76.43-65.0857-78.9894-76.43QC'd by BIOMOL
Inhibitor1.12259.675865Complete curve; partial efficacy-5.951.210.9999-66.8495-7.1736-1.20 0 0-66.096-42.6313-61.4055-66.096QC'd by Vitas
Inhibitor1.995334.026364Complete curve; partial efficacy-5.74.95490.9891-73.9118-39.8855-1.20 0 0-72.1972-47.1162-75.3813-72.1972QC'd by SigmaAldrich
Inhibitor12.589337.266562Complete curve; partial efficacy-4.911-78.1117-40.8452-1.20 0 0-68.8431-44.9463-54.9089-68.8431QC'd by Tocris
Inhibitor14.125432.429762Complete curve; partial efficacy-4.851.22160.9999-88.7022-56.2725-1.20 0 0-81.3177-58.1227-66.7029-81.3177QC'd by Enzo
Inhibitor1029.898362Complete curve; partial efficacy-53.29750.9999-76.1051-46.2067-1.20 0 0-75.9694-46.234-54.866-75.9694QC'd by Microsource
Inhibitor11.220226.849761Complete curve; partial efficacy-4.954.0950.9996-65.1082-38.2585-1.20 0 0-65.0072-38.2023-43.2866-65.0072QC'd by SigmaAldrich
Inhibitor25.118945.784461Complete curve; partial efficacy-4.61.53861-101.459-55.6745-1.20 0 0-85.8367-56.2934-62.0903-85.8367QC'd by SigmaAldrich
Inhibitor31.622832.29860Complete curve; partial efficacy-4.52.18760.9999-141.8428-109.5448-1.20 0 0-129.0357-109.6207-111.066-129.0357QC'd by Microsource
Inhibitor31.622835.977260Complete curve; partial efficacy-4.51.10.9999-99.0432-63.0659-1.20 0 0-82.9526-64.2216-69.1965-82.9526QC'd by Microsource
Inhibitor35.481337.624260Complete curve; partial efficacy-4.454.95490.9762-81.2779-43.6537-1.20 0 0-66.0936-45.7944-41.8015-66.0936QC'd by Tocris
Inhibitor35.481350.188560Complete curve; partial efficacy-4.454.44950.9982-87.6877-37.4992-1.20 0 0-66.8089-38.2236-36.8414-66.8089QC'd by Pharmacopeia
Inhibitor35.481347.340560Complete curve; partial efficacy-4.454.95490.9906-107.1544-59.8139-1.20 0 0-87.9757-61.3159-58.1701-87.9757QC'd by Prestwick Chemical; Inc.
Inhibitor5.9508124.625145Partial curve; high efficacy-5.22542.72020.864-126.7319-2.1068-2.10 0 0 0 0 0 0 0 0 0 1000-13.748-1.3723-25.9483-11.282526.65188.4521-36.83-113.80310QC'd by ChemAxon
Inhibitor11.873489.544142Partial curve; partial efficacy-4.92541.24750.9863-91.1278-1.5837-2.20 0 0 0 0 1 0 0 0 0 0-74.7046000-4.6868-8.0974-38.15161.1319-8.2196-21.8072-47.3218-74.7046QC'd by Cayman
Inhibitor25.1189267.383841Partial curve; partial efficacy-4.64.95490.8835-100.7065166.6773-2.20 0 0-71.9482116.4983215.4265-71.9482QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac1-activator-v
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.013 uMActivity at 0.025 uMActivity at 0.042 uMActivity at 0.068 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Activator112.20182659.1944100Partial curve; high efficacy-3.954.50450.99882689.2430.04562.10 0 0 0 0 02175.7605-2.186418.44120.797383.3849426.79582175.7605QC'd by Microsource
Activator0.1778128.312895Complete curve; high efficacy-6.754.95490.9927134.48516.17231.10 0 0 0 0 114.5095.603324.7938142.7655131.831127.775314.509QC'd by SigmaAldrich
Activator0.4467126.107791Complete curve; high efficacy-6.351.86170.9998123.6363-2.47141.10 0 0 0 0 10.2688-2.58447.816180.257120.2764123.38950.2688QC'd by SigmaAldrich
Activator1.122117.125490Complete curve; high efficacy-5.952.24810.9788132.426515.30111.10 0 0 0 0143.318715.809439.5652122.9227119.7824143.3187QC'd by Tocris
Activator112.20181122.177671Partial curve; high efficacy-3.954.50450.99831140.568818.39122.10 0 0 0 0922.79033.23057.588941.6506204.8302922.7903QC'd by Timtec
Activator100709.567358Partial curve; high efficacy-43.990.9988700.7079-8.85942.10 0 0 0 0 0592.8155-15.9019-8.65324.5286-20.153176.4838592.8155QC'd by CarsonNewman-SPECS
Activator79.4328826.407657Partial curve; high efficacy-4.14.0950.9972826.76670.35912.10 0 0 0 0 0665.6736-2.5729-3.4508-16.761725.5851154.5978665.6736QC'd by Prestwick Chemical; Inc.
Activator100589.932555Partial curve; high efficacy-43.24750.984613.297923.36542.10 0 0 0 0 0498.6162-5.7471.05937.654362.5313194.9599498.6162QC'd by CarsonNewman-SPECS
Activator112.2018558.656655Partial curve; high efficacy-3.954.50450.9992557.2619-1.39472.10 0 0 0 0448.681-6.8565-3.87677.063281.1858448.681QC'd by Vitas
Activator100612.475355Partial curve; high efficacy-44.50450.9972611.2868-1.18852.10 0 0 0 0 0533.4091-10.048-5.6002-8.206821.4265142.7223533.4091QC'd by Pharmacopeia
Activator100511.551853Partial curve; high efficacy-44.44950.9965517.54675.9952.10 0 0 0 0 0453.9884-10.486710.44483.974421.1983121.4017453.9884QC'd by CarsonNewman-SPECS
Activator112.2018440.198152Partial curve; high efficacy-3.954.0950.9989439.2753-0.92282.10 0 0 0 0348.6312-5.1918-3.30186.970574.6909348.6312QC'd by Sequoia
Activator100497.63552Partial curve; high efficacy-43.67720.9977486.8252-10.80982.10 0 0 0 0 0401.671-14.9427-21.3461-13.18642.6858130.5049401.671QC'd by Pharmacopeia
Activator100438.508551Partial curve; high efficacy-44.95490.9987437.7956-0.71282.10 0 0 0 0 0392.29-7.25310.2913-4.1769.366693.145392.29QC'd by Pharmacopeia
Activator56.2341819.971850Partial curve; high efficacy-4.253.24750.9993802.9227-17.0492.10 0 0 0 0787.1792-7.4836-10.9833-14.2075580.1833787.1792QC'd by NCI
Activator112.2018363.64150Partial curve; high efficacy-3.954.95490.9972355.9752-7.66582.10 0 0 0 0 0293.7089-16.73630.4741-6.1211-4.368934.2599293.7089QC'd by Pharmacopeia
Activator112.2018363.029750Partial curve; high efficacy-3.954.50450.9992370.42997.40022.10 0 0 0 0 0299.70063.69434.700413.02825.857563.7543299.7006QC'd by Pharmacopeia
Activator100295.813448Partial curve; high efficacy-43.62720.9992302.03896.22552.10 0 0 0 0 0251.69912.67988.48118.67789.650486.3825251.6991QC'd by CarsonNewman-SPECS
Activator100233.346946Partial curve; high efficacy-44.50450.9961221.7227-11.62422.10 0 0 0 0 0192.4676-6.6471-16.5394-18.4762-5.603142.3638192.4676QC'd by CarsonNewman-SPECS
Activator112.2018234.606146Partial curve; high efficacy-3.954.95490.984235.23560.62952.10 0 0 0 0 0197.01480.9163-4.51361.948217.44218.7867197.0148QC'd by Pharmacopeia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac1-inhibitor-v
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control ATA and DMSO.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.013 uMActivity at 0.025 uMActivity at 0.042 uMActivity at 0.068 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Inactive04.95490.78241.505912.540 0 0 0 0 02.50148.657916.73337.679-0.41183.23982.5014QC'd by Pharmacopeia
Inactive04.95490.5059222.540 0 0 0 0 06.253623.167131.574120.397112.323123.69316.2536QC'd by Pharmacopeia
Inactive03.06540.487561440 0 0 0 0 07.117813.853713.063510.239619.91049.84967.1178QC'd by Pharmacopeia
Inactive04.95490.8513-6.122214.540 0 0 0 0 0-2.601918.618115.697111.958910.649712.3116-2.6019QC'd by Pharmacopeia
Inactive04.95490.4441-8.935340 0 0 0 0 04.128-6.61282.85915.135-4.2457-1.68664.128QC'd by Pharmacopeia
Inactive00.90.60781.5740 0 0 0 0 03.28024.93557.52122.24671.45360.76263.2802QC'd by Pharmacopeia
Inactive0415.807823.846715.21025.400717.117711.703815.8078QC'd by Pharmacopeia
Inactive04-4.32494.35640.9262-8.26096.61363.2318-4.3249QC'd by Pharmacopeia
Inactive04.95490.3866.51640 0 0 0 0 118.561314.469622.616710.242516.25858.074118.5613QC'd by Pharmacopeia
Inactive04.95490.793515-5.385140 0 0 0 0 016.1015-1.154320.964112.456114.239511.422716.1015QC'd by Pharmacopeia
Inactive04.50450.947310.52240 0 0 0 0 08.684621.396522.306312.781710.406512.7248.6846QC'd by Pharmacopeia
Inactive00.90.72282.68042640 0 0 0 0 0-2.766319.58196.42455.7298.03594.8741-2.7663QC'd by Pharmacopeia
Inactive04.44950.86116.58.540 0 0 0 0 19.3158.510610.85386.227115.368416.53989.315QC'd by Pharmacopeia
Inactive04.95490.574110.50.708340 0 0 0 0 012.21914.1249-2.326514.46343.839910.786612.2191QC'd by Pharmacopeia
Inactive049.708413.42218.37480.333810.101818.04579.7084QC'd by Pharmacopeia
Inactive04.95490.4502-7.41418.540 0 0 0 0 0-4.51189.055914.9898-2.014610.28748.4395-4.5118QC'd by Pharmacopeia
Inactive04.95490.6758280.244340 0 0 0 0 023.04957.0826-6.46314.13492.386-6.030223.0495QC'd by Pharmacopeia
Inactive04.44950.7608-2.59256.540 0 0 0 0 18.96953.44595.67689.8855-0.0456-2.16048.9695QC'd by Pharmacopeia
Inactive02.63840.66513.52040 0 0 0 0 013.574216.035922.509821.272319.386214.340813.5742QC'd by Pharmacopeia
Inactive04-3.2632-16.2622-13.7616-11.6684-9.5243-17.6211-3.2632QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac2-activator-v2
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00246 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.011 uMActivity at 0.025 uMActivity at 0.045 uMActivity at 0.067 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Inactive04.95490.8563-9.9979-3.18240 0 0 0 0 0-8.823-2.9167-5.5515-1.8183-11.2482-10.2408-8.823QC'd by Microsource
Inactive01.53860.5644-4.854640 0 0 0 0 1-7.5471-0.6835-9.0455-3.7039-1.19033.153-7.5471QC'd by Microsource
Inactive04.95490.431-21.09492.199340 0 0 0 0 0-29.6624-1.0839-27.7771-29.2982-9.5254-9.846-29.6624QC'd by Microsource
Inactive04.95490.3341-1.3603-6.912440 0 0 0 0 1-15.5699-9.927-2.5767-5.8552-8.5221-2.3836-15.5699QC'd by Microsource
Inhibitor0.891314.13510Complete curve; partial efficacy; poor fit-6.052.12110.6534-22.6728-8.5377-1.40 0 0 0 0 0-21.1521-8.7814-12.9514-21.2535-30.9774-17.0722-21.1521QC'd by Microsource
Inactive03.1320.47250.5-4.228440 0 0 0 0 0-0.2612-1.9763-2.0592-8.107-2.12880.8201-0.2612QC'd by Microsource
Inactive04.95490.4917-10.967-2.314940 0 0 0 0 0-10.1405-1.5124-2.5506-5.4129-17.8892-4.0897-10.1405QC'd by Microsource
Inactive03.990.5924-19.9348040 0 0 0 0 0-28.6957-6.23025.7918-15.0449-23.6413-7.309-28.6957QC'd by Microsource
Inactive04.95490.4102-6.1308540 0 0 0 0 0-4.3550.82898.6021-2.8349-16.3592.161-4.355QC'd by Microsource
Inactive04.95490.369-1.5-14.336940 0 0 0 0 1-9.3021-12.78082.0015-0.2528-12.58754.4401-9.3021QC'd by Microsource
Inhibitor0.707923.62210Complete curve; partial efficacy; poor fit-6.153.06540.6513-24.5288-0.9067-1.40 0 0 0 0 1-13.9864-1.5889-9.6741-27.4469-33.3677-12.1786-13.9864QC'd by Microsource
Inactive04-22.4775-11.6889-11.6628-13.5576-20.9035-8.6191-22.4775QC'd by Microsource
Inactive00.80.7088-25.4933-11.691840 0 0 0 0 0-24.5778-16.5266-8.0765-17.2318-20.0221-22.1348-24.5778QC'd by Microsource
Inhibitor0.177819.99850Complete curve; partial efficacy; poor fit-6.754.95490.6578-21.9347-1.9361-1.40 0 0 0 0 0-23.6561-4.5301-30.7789-20.7284-19.2667-15.4849-23.6561QC'd by Microsource
Inactive010.9184-24.9585-2.733140 0 0 0 0 1-15.8401-9.7776-20.4013-20.4952-26.2154-25.1202-15.8401QC'd by Microsource
Inactive04-16.8662-15.0798-16.9114-17.163-13.1564-16.5558-16.8662QC'd by Microsource
Inactive047.75753.31266.13836.2047-2.02096.22127.7575QC'd by Microsource
Inactive043.75979.79097.02243.0975-6.896512.31463.7597QC'd by Microsource
Inactive04.95490.6335-4.9129640 0 0 0 0 0-8.84676.11915.34965.0731-9.09412.984-8.8467QC'd by Microsource
Inactive04.95490.7097-7.2734040 0 0 0 0 0-5.9151.1538-1.05870.2688-11.4778-4.1213-5.915QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:11908 靶标:N/A
External ID: RMI-FANCM-MM2
Protocol: FP HTS. Screening took place at the University of Wisconsin Small Molecule Screening and Synthesis Facility. A master mix of RMI core complex and F-MM2 (30 microL per well) was plated in black 384 shallow well plates (ThermoFisher, Waltham, MA), using a BioTek "MicroFlo Select" reagent dispenser. Compounds were added using a Beckman FX liquid handler; 0.33 microL of 10 mM stock was added for a final compound concentration of 33 microM. MM2 and cMM2 were each added to 4 wells of master mix per plate to a final concentration of 10 muM to serve as controls. Following compound addition, plates were covered, centrifuged briefly, and incubated for 20 minutes at room temperature. FP measurements were taking using a Tecan "Safire 2" microplate reader. Instrument settings were as follows: top read, EX 470, EM 525/20, G-factor 0.89947. A suitable gain was calculated from the first plate of each day. Z' scores for were calculated for each plate; plates with Z' scores <0.5 were rerun prior to analysis.
Comment:
Concentration uMData readout
3355
3363
3365
3363
3361
3362
3361
3358
3371
3361
3364
3383
33158
3384
33104
3360
3362
3359
3358
3359
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac2-inhibitor-v2
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0009200000 uMActivity at 0.00184 uMActivity at 0.00456 uMActivity at 0.00471 uMActivity at 0.00850 uMActivity at 0.018 uMActivity at 0.034 uMActivity at 0.050 uMActivity at 0.090 uMActivity at 0.151 uMActivity at 0.235 uMActivity at 0.457 uMActivity at 0.814 uMActivity at 1.171 uMActivity at 2.284 uMActivity at 4.113 uMActivity at 5.853 uMActivity at 11.42 uMActivity at 20.49 uMActivity at 29.59 uMActivity at 56.64 uMActivity at 111.7 uMActivity at 150.6 uMActivity at 238.8 uMActivity at 452.6 uMActivity at 611.0 uMCompound QC
Inactive03.62720.8626-16.9749340 0 0 0 0 0-11.35224.4122-0.18693.8551-9.0486-22.4791-11.3522QC'd by SigmaAldrich
Inactive01.210.9115126.540 0 0 0 0 03.087922.522231.966122.849617.27176.55893.0879QC'd by NCI
Inactive00.30.7243-12.89953840 0 0 0 0 0-10.749628.516821.95465.20966.073811.3009-10.7496QC'd by Prestwick Chemical; Inc.
Inactive04.95490.8029-15.6993-1.540 0 0 0 0 0-11.416-1.5504-1.249-4.6581-0.42660.4639-11.416QC'd by BIOMOL
Inactive04.95490.6678-24.46023.435940 0 0 0 0 1-5.46512.8722.434-38.4104-25.2406-9.2436-5.4651QC'd by BIOMOL
Inactive02.40640.421511740 0 0 0 0 05.872919.320214.88288.633224.90711.29795.8729QC'd by BIOMOL
Inactive00.60.7078-8.313814.540 0 0 0 0 0-10.777711.81871.99321.9062-11.5115-0.0866-10.7777QC'd by BIOMOL
Inactive03.990.91612.52940 0 0 0 0 011.321625.351110.278212.692812.042515.059611.3216QC'd by BIOMOL
Inactive04.95490.7598-8.0307240 0 0 0 0 0-6.9632-1.91335.8317-9.609-8.7246-6.018-6.9632QC'd by SigmaAldrich
Inactive00.70.6402-18.8089-2.373540 0 0 0 0 0-14.8407-3.9662-6.7181-0.3112-9.968-9.2615-14.8407QC'd by Microsource
Inactive04.95490.9739-11.7501240 0 0 0 0 0-11.69293.0780.24372.2683-12.7084-10.568-11.6929QC'd by Microsource
Inactive00.50.7605-11.0605640 0 0 0 0 0-14.63373.6876-3.5123-6.8473-7.5675-5.2666-14.6337QC'd by BIOMOL
Inactive04-7.534.7778-6.7829-15.1322-23.6499.0847-7.53QC'd by Prestwick Chemical; Inc.
Inactive04.95490.6409-3.29491440 0 0 0 0 112.981817.6514.10220.62192.497-3.579112.9818QC'd by BIOMOL
Inactive01.82650.7407-32.7287-10.937340 0 0 0 0 0-28.3802-13.7631-19.1044-5.7811-12.8137-32.2739-28.3802QC'd by Tocris
Activator39.810746.5380Single point of activity-4.44.44950.745456.645810.107830 0 0 0 0 117.141513.503225.583214.4646.953849.110217.1415QC'd by SigmaAldrich
Inactive04.95490.5359-17.72063.540 0 0 0 0 0-16.8505-6.86613.1002-5.400912.3928-11.0619-16.8505QC'd by SigmaAldrich
Inactive04.95490.6571.108210.540 0 0 0 0 110.717211.35185.125315.2488-0.32652.247610.7172QC'd by Prestwick Chemical; Inc.
Inactive00.70.842-14.440710.540 0 0 0 0 0-8.700613.02386.27927.28923.56910.9878-8.7006QC'd by BIOMOL
Inactive01.010.87182.4065-26.947540 0 0 0 0 1-20.1909-25.9748-30.373-20.9376-21.2882-7.9946-20.1909QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:TDP1 protein [Homo sapiens]
External ID: TDP1100
Protocol: DT40-hTDP1 cells without 20 nM Camptothecin (add 20 microL of DMSO in 1 L of cell culture medium) were dispensed at 400 cells/5microL/well in tissue culture treated 1536-well white wall/solid bottom assay plates (Greiner Bio-One North America, NC, U.S.A.) using a Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). 23 nL compounds and controls were transferred using the pin tool (Kalypsys, San Diego, CA, USA) to the assay plates. The assay plates were then incubated at 37 masculineC for a minimum 48 hr. Three microL of Cell Titer Glo solution was added to the plates and incubated at RT in dark for 30 min. Luminescence was read using ViewLux (Perkin Elmer) with 1 sec exposure slow speed, high gain and 2x binning.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000295000 uMActivity at 0.0000590000 uMActivity at 0.0001503265 uMActivity at 0.0002712146 uMActivity at 0.0005895491 uMActivity at 0.00117 uMActivity at 0.00179 uMActivity at 0.00299 uMActivity at 0.00672 uMActivity at 0.014 uMActivity at 0.026 uMActivity at 0.040 uMActivity at 0.074 uMActivity at 0.167 uMActivity at 0.363 uMActivity at 0.628 uMActivity at 0.975 uMActivity at 1.849 uMActivity at 4.119 uMActivity at 9.037 uMActivity at 15.83 uMActivity at 21.08 uMActivity at 46.23 uMActivity at 92.54 uMActivity at 165.6 uMCompound QC
Inactive04-3.0662-2.41261.9741-4.0617-0.6298-3.0662QC'd by "Chem Div"
Inactive04.95490.7346-0.808-4.30840 0 0 0 0-0.431-4.3080.8987-1.5892-1.522-0.431QC'd by "Chem Div"
Inactive04.95490.6448-12.51274.558540 0 0 0 0-9.75096.55851.6006-0.810411.697-9.7509QC'd by "Chem Div"
Inhibitor18.356499.037841Partial curve; high efficacy-4.73622.84730.9985-99.5803-0.5425-2.10 0 0 0 0-92.8278-1.5772-1.93651.8258-13.1847-92.8278QC'd by "Chem Div"
Inhibitor29.092942.181510Single point of activity-4.53624.95490.9879-50.8391-8.6577-30 0 0 0 0-46.8496-7.6387-8.6142-11.6103-6.66-46.8496QC'd by "Chem Div"
Inhibitor18.3564123.871841Partial curve; high efficacy-4.73621.62590.9975-121.45782.414-2.10 0 0 0 0-98.82245.0098-1.1767-0.5372-27.2941-98.8224QC'd by "Chem Div"
Inhibitor14.581109.907342Partial curve; high efficacy-4.83621.82650.9637-106.40863.4987-2.10 0 0 0 0-94.670912.0352-9.70946.0901-28.9742-94.6709QC'd by "Chem Div"
Inactive00.30.9096-34.0578-3.769740 0 0 0 0-28.0098-7.7697-15.2699-21.1534-19.3019-28.0098QC'd by "Chem Div"
Inhibitor29.092990.897810Single point of activity-4.53624.44950.9936-90.33680.561-30 0 0 0 0-79.96355.0637-2.1732-1.69030.5114-79.9635QC'd by "Chem Div"
Inactive00.30.426615.2787-6.721340 0 0 0 010.4803-5.72138.5589-5.30466.71910.4803QC'd by "Chem Div"
Inactive01.96730.6089-9.50825.296840 0 0 0 0-7.95747.2968-1.890310.39461.3036-7.9574QC'd by "Chem Div"
Inhibitor16.360145.504710Single point of activity-4.78624.95490.9618-49.1256-3.6209-30 0 0 0 0-48.9315-7.5358-6.3332.7698-6.0371-48.9315QC'd by "Chem Div"
Inactive0-5.28620.80.9747-26.74278.437240 0 0 0 0-20.71279.43722.29650.248-14.6534-20.7127QC'd by "Chem Div"
Inactive04.95490.9526-10.392812.159440 0 0 0 0-10.30087.659413.806714.3816-9.7278-10.3008QC'd by "Chem Div"
Inactive02.25260.9456-15.0824-3.824740 0 0 0 0-14.7061-2.8247-5.6912-3.1226-9.4063-14.7061QC'd by "Chem Div"
Inhibitor12.995378.844742Partial curve; high efficacy-4.88621.55790.9935-82.5518-3.7072-2.10 0 0 0 0-72.8175-6.4603-0.3489-8.7793-32.8366-72.8175QC'd by "Chem Div"
Inhibitor18.356449.742410Single point of activity-4.73622.84730.9797-46.14163.6008-30 0 0 0 0-42.7679-0.89924.9836.9739-2.5062-42.7679QC'd by "Chem Div"
Inactive04.95490.8308-9.79910.472540 0 0 0 0-5.08718.47258.256110.070916.081-5.0871QC'd by "Chem Div"
Inactive01.88510.9722-5.76856.220540 0 0 0 0-5.0636.2205-1.5445-7.1037-5.5678-5.063QC'd by "Chem Div"
Inactive00.30.842-31.92493.17440 0 0 0 0-26.7418-0.826-13.6909-13.1344-14.0869-26.7418QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:67.9K protein [Vaccinia virus]
External ID: Vaccinia-p2mCherry
Protocol: A549 cells were plated at a concentration of approximately 6,000 cells per well in clear-bottom black-walled plates. Compounds were added to the assay plate followed by addition of virus (LREV) that expresses the Venus fluorescent protein early in viral ininfection. During the late viral infection, mCherry was also added to the plate at an MOI of 10 (~ 60,000 plaque forming units (PFU) of virus). Following virus addition, plates were incubated in a tissue-culture incubator for 12-18 hours. At increasing times postinfection, fluorescence from both Venus and mCherrry was determined using a plate-reader and standard conditions for observing Venus fluorescence (EX515/EM530) and mCherry fluorescence (EX587/EM610). In each plate, positive controls (virus infection in the presence of 1% DMSO only) and an inhibitory drug control (AraC at 500 nM) was included and used to normalize the data.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00111 uMActivity at 0.00284 uMActivity at 0.00446 uMActivity at 0.00891 uMActivity at 0.015 uMActivity at 0.029 uMActivity at 0.036 uMActivity at 0.073 uMActivity at 0.113 uMActivity at 0.149 uMActivity at 0.293 uMActivity at 0.487 uMActivity at 0.726 uMActivity at 1.458 uMActivity at 2.011 uMActivity at 3.331 uMActivity at 5.199 uMActivity at 7.343 uMActivity at 13.78 uMActivity at 20.90 uMActivity at 36.53 uMActivity at 60.71 uMActivity at 87.88 uMActivity at 127.3 uMActivity at 194.0 uMCompound QC
Inactive01.39870.9996-13.0836-0.585340 0 0 1-0.8016-2.9877-9.467-12.5697-0.8016QC'd by "Asinex Ltd."
Inhibitor12.589340.511110Single point of activity-4.94.50450.9991-45.3562-4.8451-30 0 0 0-45.0493-5.3378-3.9936-8.2693-45.0493QC'd by "Asinex Ltd."
Inactive040-2.0352000QC'd by "Asinex Ltd."
Inactive04000-0.99410QC'd by "Asinex Ltd."
Inactive04.954910-13.633540 0 0 00-12.1946000QC'd by "Asinex Ltd."
Inactive0400000QC'd by "Asinex Ltd."
Inactive04-13.3369-12.1444-5.0835-13.8274-13.3369QC'd by "Asinex Ltd."
Inactive040-4.5112-3.956800QC'd by "Asinex Ltd."
Inactive0400000QC'd by "Asinex Ltd."
Inactive01.80790.9998-19.4131.540 0 0 1-2.29920-11.3763-18.6775-2.2992QC'd by "Asinex Ltd."
Inactive04.95490.77214-15.639840 0 0 00-10.469-15.9421-20.94990QC'd by "Asinex Ltd."
Inactive04.95490.9987-20.1455-0.540 0 0 0-19.28790-0.8113-0.6866-19.2879QC'd by "Asinex Ltd."
Inactive04.95490.9999-7.3207040 0 0 0-6.934000-6.934QC'd by "Asinex Ltd."
Inactive04-10.13410-23.8022-3.1543-10.1341QC'd by "Asinex Ltd."
Inactive01.82650.9999-31.5926140 0 0 1-8.44790-12.323-29.2439-8.4479QC'd by "Asinex Ltd."
Inactive00.70.95422-18.098140 0 0 00-15.9151-9.0083-6.24390QC'd by "Asinex Ltd."
Inactive04.95490.79940.5884-8.240 0 0 0-1.1763-9.1365-5.7126-9.75-1.1763QC'd by "Asinex Ltd."
Inactive00.60.9653-16.23140.75640 0 0 0-14.3595-3.5367-8.6422-10.5182-14.3595QC'd by "Asinex Ltd."
Inactive04-3.3063-1.5829-0.45720-3.3063QC'd by "Asinex Ltd."
Inactive04.95490.7973-6.6878-1.540 0 0 10-2.54350-5.57310QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:TDP1 protein [Homo sapiens]
External ID: TDP1101
Protocol: DT40-hTDP1 cells with 20 nM Camptothecin (add 20 microL of 1 mM CPT stock in 1 L of cell culture medium) were dispensed at 400 cells/5microL/well in tissue culture treated 1536-well white wall/solid bottom assay plates (Greiner Bio-One North America, NC, U.S.A.) using a Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). 23 nL compounds and controls were transferred using the pin tool (Kalypsys, San Diego, CA, USA) to the assay plates. The assay plates were then incubated at 37 masculineC for a minimum 48 hr. Three microL of Cell Titer Glo solution was added to the plates and incubated at RT in dark for 30 min. Luminescence was read using ViewLux (Perkin Elmer) with 1 sec exposure slow speed, high gain and 2x binning.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000295000 uMActivity at 0.0000590000 uMActivity at 0.0001503265 uMActivity at 0.0002712146 uMActivity at 0.0005895491 uMActivity at 0.00117 uMActivity at 0.00179 uMActivity at 0.00299 uMActivity at 0.00672 uMActivity at 0.014 uMActivity at 0.026 uMActivity at 0.040 uMActivity at 0.074 uMActivity at 0.167 uMActivity at 0.363 uMActivity at 0.628 uMActivity at 0.975 uMActivity at 1.849 uMActivity at 4.119 uMActivity at 9.037 uMActivity at 15.83 uMActivity at 21.08 uMActivity at 46.23 uMActivity at 92.54 uMActivity at 165.6 uMCompound QC
Inhibitor20.5962118.89141Partial curve; high efficacy-4.68622.30310.9994-116.16692.7241-2.10 0 0 0 0-99.94512.72414.25720.7717-13.7373-99.9451QC'd by "Asinex Ltd."
Inactive00.80.9749-16.17712.005740 0 0 0 0-13.14662.00571.2486-2.8352-5.7162-13.1466QC'd by "Asinex Ltd."
Inactive04.95490.6148-11.8012.205940 0 0 0 0-9.7999-4.79413.64526.73633.1419-9.7999QC'd by "Asinex Ltd."
Inactive0-5.03622.33320.9795-28.8852-5.272340 0 0 0 0-28.1997-7.2723-3.3531-4.7215-17.5124-28.1997QC'd by "Asinex Ltd."
Inhibitor5.173594.688584Complete curve; high efficacy-5.28622.90230.9917-96.1842-1.4957-1.10 0 0 0 0-96.0073-7.53084.5779-6.8491-81.1577-96.0073QC'd by "Asinex Ltd."
Inhibitor18.356494.01210Single point of activity-4.73623.62720.9999-96.5346-2.5226-30 0 0 0 0-93.107-2.9055-1.9361-2.363-9.7613-93.107QC'd by "Asinex Ltd."
Inactive04.95490.8434-31.3086-2.25540 0 0 0 0-27.0497-0.755-10.5210.92280.8125-27.0497QC'd by "Asinex Ltd."
Inactive04.44950.7303-25.728-7.249240 0 0 0 0-25.3982-8.7492-13.51280.9177-19.0413-25.3982QC'd by "Asinex Ltd."
Inhibitor20.5962100.541141Partial curve; high efficacy-4.68622.09370.998-104.3872-3.8461-2.10 0 0 0 0-88.9539-4.1551-2.0443-7.1093-18.8654-88.9539QC'd by "Asinex Ltd."
Inhibitor29.092991.413310Single point of activity-4.53624.95490.9947-88.35973.0536-30 0 0 0 0-79.845-1.16852.65594.53855.7131-79.845QC'd by "Asinex Ltd."
Inactive04.95490.786-1.849912.995440 0 0 0 116.19477.995418.22950.5262-1.875716.1947QC'd by "Asinex Ltd."
Inactive04.95490.9259-4.54544.383940 0 0 0 0-3.72395.38394.7472.6664.8335-3.7239QC'd by "Asinex Ltd."
Inactive0-6.23624.95490.9762-1.408619.454340 0 0 0 01.208619.454317.7088-3.3481-2.37561.2086QC'd by "Asinex Ltd."
Inactive04.95490.4363-4.5616-11.561640 0 0 0 0-4.5336-11.5616-1.6565-10.5162-2.2482-4.5336QC'd by "Asinex Ltd."
Inactive00.70.98896.5184-6.981640 0 0 0 02.8921-7.4816-5.7762-3.9537-1.52422.8921QC'd by "Asinex Ltd."
Inactive04.95490.5926-22.1394-0.155940 0 0 0 0-20.8088-4.1559-8.30412.2914-0.0696-20.8088QC'd by "Asinex Ltd."
Inhibitor29.092964.218610Single point of activity-4.53624.95490.9684-70.1227-5.9041-30 0 0 0 0-64.396-9.2052-0.418-11.9994-2.9068-64.396QC'd by "Asinex Ltd."
Inactive01.210.9644-26.92634.843740 0 0 0 0-17.96476.84374.96630.5719-1.9517-17.9647QC'd by "Asinex Ltd."
Inactive04.95490.9261-29.9871.936440 0 0 0 0-26.99980.4364-0.7582-0.45327.9656-26.9998QC'd by "Asinex Ltd."
Inactive04.0950.45761.780312.60740 0 0 0 06.613211.107-4.99860.1865.25796.6132QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:DNA polymerase kappa [Homo sapiens]
External ID: PolK100
Protocol: Three microliters of reagents (buffer in column 3 and 4 as negative control and 10 nM Pol kappa in columns 1, 2, and 5-48) were dispensed into a 1536-well black solid-bottom plate. Compounds (23 nL) were transferred via Kalypsys pin tool equipped with 1536-pin array. The plates were then incubated for 15 min at room temperature, and 1 uL substrate (50 nM final concentration) were then added to start the reaction and kinetically read twice at 0 min and 10 min on the Viewlux reader
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003270000 uMActivity at 0.0007732774 uMActivity at 0.00163 uMActivity at 0.00369 uMActivity at 0.00818 uMActivity at 0.020 uMActivity at 0.030 uMActivity at 0.047 uMActivity at 0.101 uMActivity at 0.151 uMActivity at 0.243 uMActivity at 0.477 uMActivity at 0.759 uMActivity at 1.287 uMActivity at 2.393 uMActivity at 3.818 uMActivity at 6.336 uMActivity at 11.99 uMActivity at 19.37 uMActivity at 31.37 uMActivity at 60.11 uMActivity at 107.2 uMActivity at 158.4 uMActivity at 229.0 uMCompound QC
Inactive40 0 0 0 01.4694-3.5669-6.2352.85861.80421.4694QC'd by "Chem Div"
Inactive40 0 0 0 0-4.26318.22188.081110.2927-3.9947-4.2631QC'd by "Chem Div"
Inactive40 0 0 0 06.03690.3398-2.1048-8.1695-3.68226.0369QC'd by "Chem Div"
Inactive4-2.05651.7294-3.5894-1.2575-0.5402-2.0565QC'd by "Chem Div"
Inactive40 0 0 0 12.31491.00484.6369-1.9963-3.35432.3149QC'd by "Chem Div"
Inactive47.27487.15156.13721.51975.23327.2748QC'd by "Chem Div"
Inactive40 0 0 0 01.006-3.3873-7.786-9.3037-9.17611.006QC'd by "Chem Div"
Inactive40 0 0 0 0-0.0368-9.4458-10.5155-9.0065-12.9141-0.0368QC'd by "Chem Div"
Inactive40 0 0 0 02.6-7.8084-12.3007-2.0954-6.68872.6QC'd by "Chem Div"
Inactive40 0 0 0 0-11.4867-18.9051-17.4955-19.0735-9.6682-11.4867QC'd by "Chem Div"
Inactive40 0 0 0 0-7.5605-17.2173-11.0038-16.5656-22.4025-7.5605QC'd by "Chem Div"
Inactive4-7.5451-1.1939-1.3084-5.8268-5.3206-7.5451QC'd by "Chem Div"
Inactive40 0 0 0 1-5.5852-4.3753-1.0046-3.1641-10.1524-5.5852QC'd by "Chem Div"
Inactive40 0 0 0 01.1172-6.03917.01189.04461.65331.1172QC'd by "Chem Div"
Inactive42.33591.25181.6626-0.9325-0.91942.3359QC'd by "Chem Div"
Inactive40 0 0 0-19.53540.3984-4.11472.1883-19.5354QC'd by "Chem Div"
Inactive4-5.6552-4.6769-1.9378-0.5867-3.224-5.6552QC'd by "Chem Div"
Inactive4-11.3738-10.4148-13.8912-10.4252-7.8961-11.3738QC'd by "Chem Div"
Inactive4-6.1571-8.7102-2.9113-5.2229-3.4369-6.1571QC'd by "Chem Div"
Inactive40 0 0 0 1-7.3803-8.8177-11.1654-6.5301-15.9483-7.3803QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:11924 靶标:N/A
External ID: CGM data for Cell Systems paper Dec 2015
Protocol: Yeast strains and Media:
All S. cerevisiae deletion strains were obtained from the Euroscarf deletion collection. The wild type parental strain for this collection is BY 4741 MATa his31 leu20 met150 ura30. An isogenic pdr1pdr3 strain (MT2481) was created using PDR1::nat and PDR::URA3 deletion cassettes. All strains were grown and screened in synthetic complete (SC) medium with 2% glucose.

Handling:
Strains were seeded at 50,000 cells per well in a volume of 100 L in 96 well plates followed by addition of 2 L of 1 mM compound stock for final concentration of 20 M. Screens were conducted in technical duplicate using a Biomek FX liquid handling workstation with an integrated stacker carousel. DMSO solvent only controls and 10 uM cycloheximide positive controls were seeded in columns 1 and 12 of each assay plate. Plates were incubated at 30 C without shaking for approximately 18 h or until culture saturation was achieved for the solvent controls. Cultures were resuspended by shaking on the robotic platform prior to reading OD600 values on either Tecan M1000 or Tecan Sunrise plate readers.

Analysis procedure:
All data was subjected to the following workflow:
1. Consistent spatial effects on growth across plates were corrected by Lowess regression using an empirically estimated sliding window of 1/3 and normalized based on plate median.
2. If more than 30% of compounds were active within a plate, data was normalized to DMSO controls.
3. Median normalization was applied to all plates and experiments.
4. Z-factors for growth inhibition were calculated using the median and the interquartile range (IQR) by fitting a normal distribution with N(1,IQR) to the experimental data. In addition, we calculated the Z-factor, percent inhibition and normalized OD values for manual validation.
5. Data points with high variation between replicates (> 3 MAD) were removed as inconsistent outliers.

BioAssay submission file header:

Pubchem_ext_datasource_regid: compound identifier used in on chemgrid.org/cgm
Orf yeast gene deletion (open reading frame)
Sym# yeast gene deletion gene symbol
Raw OD read 1 first replicate
Raw OD read 2 second replicate
Normalized OD average normalized read based on workflow described above
Z_score Z-Score calculated based on kernel density distribution from normalized average reads per screen
P_value p-value calculated based on kernel density distribution calculated from average reads per screen
Non replicate test for non-replicates between first and second replicate
Pubchem_activity_outcome pubchem activity outcome
Cryptagen if compound identifier fulfilled cryptagen rule of activity in at least 4 and not more than 2/3rds of screens per library
Bioactivity sensitive if compound decreases fitness or resistant if compound increases fitness compared to negative control
Comment:
orfsymraw OD read 1raw OD read 2normalized OD averagez_scorep_valuenon replicatecryptagenbioactivity
YMR263WSAP300.81090.82411.007920.6765250.25126700
YMR263WSAP300.70740.70450.999472-0.02700660.43853300
YMR263WSAP300.71320.82811.017960.6225070.27234601
YMR263WSAP300.80970.70871.008750.7614850.22641600
YMR263WSAP300.69810.82591.01050.3744620.35427900
YMR263WSAP300.80850.70631.005020.4370360.33193100
YMR263WSAP300.65350.68970.990762-0.3283280.37139400
YMR263WSAP300.81330.69411.007170.5988890.29095200
YMR263WSAP300.68670.80190.976773-0.8247460.20524700
YMR263WSAP300.78360.68620.991018-0.7716340.22038900
YMR263WSAP300.59950.61390.893377-3.803870.00037803201
YMR263WSAP300.62710.80940.962532-1.306830.10774100
YMR263WSAP300.68780.69570.980366-0.6848680.24993400
YMR263WSAP300.68680.69620.978746-0.7416890.23281100
YMR263WSAP300.65410.64840.937529-2.232410.02007301
YMR263WSAP300.81210.82591.009720.8309410.20515300
YMR263WSAP300.68160.69681.002080.06816690.4595700
YMR263WSAP300.70580.79830.990309-0.3607950.36655800
YMR263WSAP300.78730.80340.980792-1.660550.049953200
YMR263WSAP300.69170.70120.997639-0.08757040.46520801
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:67.9K protein [Vaccinia virus]
External ID: Vaccinia-p2Venus
Protocol: A549 cells were plated at a concentration of approximately 6,000 cells per well in clear-bottom black-walled plates. Compounds were added to the assay plate followed by addition of virus (LREV) that expresses the Venus fluorescent protein early in viral infection. During the late viral infection, mCherry was also added to the plate at an MOI of 10 (~ 60,000 plaque forming units (PFU) of virus). Following virus addition, plates were incubated in a tissue-culture incubator for 12-18 hours. At increasing times post-infection, fluorescence from both Venus and mCherrry was determined using a plate-reader and standard conditions for observing Venus fluorescence (EX515/EM530) and mCherry fluorescence (EX587/EM610). In each plate, positive controls (virus infection in the presence of 1% DMSO only) and an inhibitory drug control (AraC at 500 nM) was included and used to normalize the data.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00111 uMActivity at 0.00284 uMActivity at 0.00446 uMActivity at 0.00891 uMActivity at 0.015 uMActivity at 0.029 uMActivity at 0.036 uMActivity at 0.073 uMActivity at 0.113 uMActivity at 0.149 uMActivity at 0.293 uMActivity at 0.487 uMActivity at 0.726 uMActivity at 1.458 uMActivity at 2.011 uMActivity at 3.331 uMActivity at 5.199 uMActivity at 7.343 uMActivity at 13.78 uMActivity at 20.90 uMActivity at 36.52 uMActivity at 60.71 uMActivity at 87.88 uMActivity at 127.3 uMActivity at 194.0 uMCompound QC
Inactive01.46410.71-12.454-240 0 0 0-11.2117-5.20930.6206-7.2594-11.2117QC'd by "Chem Div"
Inactive04-11.3429-16.0267-12.2608-14.6132-11.3429QC'd by "Chem Div"
Inactive01.62590.9272-14.3148-0.87740 0 0 0-15.2623-7.8142-13.6096-13.0621-15.2623QC'd by "Chem Div"
Inactive04-12.3142-9.814-12.586-8.4662-12.3142QC'd by "Chem Div"
Inactive04-8.2677-9.1999-12.2836-11.2753-8.2677QC'd by "Chem Div"
Inactive04.50450.9238-23.3577-9.005740 0 0 0-23.2147-6.6714-11.5717-9.7492-23.2147QC'd by "Chem Div"
Inhibitor11.220218.895721Partial curve; partial efficacy-4.953.51170.9065-31.7758-12.8801-2.20 0 0 0-31.4798-16.0985-9.0667-16.5103-31.4798QC'd by "Chem Div"
Inactive04.95490.8003-13.5254-8.878340 0 0 0-13.3545-10.4528-7.3986-12.9731-13.3545QC'd by "Chem Div"
Inactive02.33320.9015-5.5393840 0 0 0-5.44945.481810.30710-5.4494QC'd by "Chem Div"
Inactive01.96730.9741-21.6735-12.493740 0 0 0-21.3946-13.4008-12.078-16.6303-21.3946QC'd by "Chem Div"
Inactive04-5.6419-17.3934-2.7552-14.5706-5.6419QC'd by "Chem Div"
Inactive04.95490.8944-16.0102-8.684840 0 0 0-15.0085-7.2373-9.9603-8.6791-15.0085QC'd by "Chem Div"
Inactive01.55790.9997-19.5854-2.051340 0 0 1-5.8527-2.9594-9.4187-17.9878-5.8527QC'd by "Chem Div"
Inactive00.90.997418-20.238340 0 0 012.7737-17.6986-10.21151.105512.7737QC'd by "Chem Div"
Inactive01.88510.9998-14.291-6.778340 0 0 1-6.726-6.8986-8.4505-13.1591-6.726QC'd by "Chem Div"
Inactive00.90.9901-24.8053-6.556940 0 0 0-19.0044-6.7141-9.2211-12.2131-19.0044QC'd by "Chem Div"
Inhibitor1025.752521Partial curve; partial efficacy-54.95490.9958-34.5683-8.8157-2.20 0 0 0-34.709-9.7184-7.7631-13.3604-34.709QC'd by "Chem Div"
Inactive00.50.7446-13.2445-2.110940 0 0 0-9.3704-2.5924-6.2168-4.8236-9.3704QC'd by "Chem Div"
Inactive04.95490.8017-7.4285-18.016840 0 0 0-7.4434-13.764-5.7738-9.5578-7.4434QC'd by "Chem Div"
Activator31.6228490Partial curve; high efficacy-4.50.80.9998651142.10 0 0 1118.3965112.9568110.0983102.4909118.3965QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:DNA dC->dU-editing enzyme APOBEC-3G [Homo sapiens]
External ID: VIFG001
Protocol: 5 uL of 700 cells/well of A3G-YFP cells are dispensed into black, clear bottom plates. The plates are incubated overnight at 37 deg C. 23 nL of compounds are added by pintool. The plates are incubated overnight at 37 deg C and then read on the TTP Acumen (Ex 488/ Em 500-530).
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0005900000 uMActivity at 0.00295 uMActivity at 0.015 uMActivity at 0.074 uMActivity at 0.369 uMActivity at 1.840 uMActivity at 9.220 uMActivity at 46.10 uMCompound QC
Inactive40 0 0 0 0 0 0 1-2.8899-6.1899-7.5624-5.0442-5.2691-7.4083-3.06250.8337-2.8899QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 0-11.8860.77993.3283-1.6574-0.379-0.0407-0.17333.2895-11.886QC'd by "Tocris"
Inactive4-8.03070.0881-3.9451-3.8178-5.1347-11.9909-2.936-1.1932-8.0307QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 0-1.5931.55610.90321.2235-3.4696-0.9657-0.0842-2.0495-1.593QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 0-0.0788-4.93370.46-2.58070.74460.0136-2.3008-1.5552-0.0788QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 14.2624-0.43121.7854-0.00565.86621.0675-7.88061.24754.2624QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 1-4.0346-8.947-0.9086-0.5189-7.1836-5.169-5.6634-29.5845-4.0346QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 05.7591-1.40682.7508-0.18152.97853.6943.9998-0.30155.7591QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 1-5.38442.4078-5.9512-3.7241-3.39922.0570.63310.8532-5.3844QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 0-2.2453-3.73630.69420.601-1.9285-1.36094.35161.1697-2.2453QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 12.3324-0.53550.12434.30394.14566.66133.39364.33212.3324QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 16.79776.2063-2.5612-1.1693-0.51280.1248-0.35210.73976.7977QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 02.0217-0.17920.1152-0.6021-3.36050.82374.5925-1.22172.0217QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 10.44250.3833-4.4422-0.573-2.9321.05940.9653-13.93480.4425QC'd by "Tocris"
Inactive4-3.4074-6.9944-1.67220.3863-3.98122.4758-6.1635-1.5512-3.4074QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 1-4.3806-4.5738-3.6173-2.01740.1354-5.2732-8.3845-9.4028-4.3806QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 0-2.4802-2.1041.68161.34423.67763.5172-1.5608-3.0137-2.4802QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 1-0.87761.878-0.06344.212-1.14164.9935-0.0837-6.743-0.8776QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 12.00950.0313-0.3445-1.2227-5.0231-0.6641.2992-8.02462.0095QC'd by "Tocris"
Inactive40 0 0 0 0 0 0 1-0.554-4.5098-3.3182-1.7265-0.7027-6.0998-4.6423-10.6714-0.554QC'd by "Tocris"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Histone deacetylase 6
External ID: CHEMBL4808149
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL1865
ChEMBL Target Name: Histone deacetylase 6
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: Fraunhofer Institute HDAC6 screening
Standard TypeStandard RelationStandard ValueStandard Text ValueStandard UnitsData Validity Comment
Inhibition=-13.63%Outside typical range
Inhibition=-37.85%Outside typical range
Inhibition=-31.68%Outside typical range
Inhibition=-40.84%Outside typical range
Inhibition=-33.51%Outside typical range
Inhibition=-11.71%Outside typical range
Inhibition=-12.48%Outside typical range
Inhibition=8.75%
Inhibition=-57.22%Outside typical range
Inhibition=-43.91%Outside typical range
Inhibition=-42.06%Outside typical range
Inhibition=25.26%
Inhibition=31.78%
Inhibition=-63.83%Outside typical range
Inhibition=1.14%
Inhibition=-17.63%Outside typical range
Inhibition=14.49%
Inhibition=3.28%
Inhibition=10.08%
Inhibition=13.93%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Histone deacetylase 6
External ID: CHEMBL4808150
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL1865
ChEMBL Target Name: Histone deacetylase 6
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: Fraunhofer Institute HDAC6 screening
Standard TypeStandard RelationStandard ValueStandard Text ValueStandard UnitsData Validity Comment
Inhibition=-7.39%
Inhibition=-3.08%
Inhibition=97.8%
Inhibition=-9.09%
Inhibition=47.05%
Inhibition=-5.94%
Inhibition=-0.48%
Inhibition=-2.98%
Inhibition=1.42%
Inhibition=12.25%
Inhibition=-2.13%
Inhibition=-4.43%
Inhibition=4.53%
Inhibition=-5.82%
Inhibition=10.36%
Inhibition=-1.3%
Inhibition=12.9%
Inhibition=-3.37%
Inhibition=3.17%
Inhibition=-0.97%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: StopGo1
Protocol: 3000 Hek-293T-WT cells were plated overnight before adding 23 nL of FireFly inhibitors per well using a pintool workstation (Kalypsys) followed by incubation for 4 hr. Luciferase activity was then measured using Amplite Luciferase Reagent.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.023 uMActivity at 0.029 uMActivity at 0.047 uMActivity at 0.084 uMActivity at 0.127 uMActivity at 0.212 uMActivity at 0.303 uMActivity at 0.463 uMActivity at 0.774 uMActivity at 1.183 uMActivity at 2.152 uMActivity at 2.856 uMActivity at 4.631 uMActivity at 6.701 uMActivity at 11.26 uMActivity at 16.91 uMActivity at 27.01 uMActivity at 39.83 uMActivity at 57.93 uMActivity at 97.38 uMActivity at 146.4 uMActivity at 210.0 uMActivity at 304.0 uMCompound QC
Inactive04-6.0625-2.3623-0.2802-5.2775-6.0625QC'd by Evotec (US) Inc.
Inhibitor35.481340.773610Single point of activity-4.452.40640.933-44.7736-4-30 0 0 0-35.05580-9.6533-5.4245-35.0558QC'd by Evotec (US) Inc.
Inactive0-5.853.92950.9968-13.4932340 0 0 0-13.15412.8182-11.1738-14.161-13.1541QC'd by UrkORgSynthesis Ltd
Inactive0-5.14.95490.889213.5-3.562340 0 0 1-8.0174-0.4429-6.301911.0739-8.0174QC'd by Evotec (US) Inc.
Inactive04-15.8272-9.3466-13.7699-18.4456-15.8272QC'd by Evotec (US) Inc.
Inactive0-5.72.40640.8108-13.04340.434140 0 0 0-9.5936-0.0549-7.5602-16.7029-9.5936QC'd by Evotec (US) Inc.
Inactive04-11.635-18.2363-13.8009-16.9167-11.635QC'd by Evotec (US) Inc.
Inactive04-12.2857-9.6332-6.6135-15.2325-12.2857QC'd by Evotec (US) Inc.
Activator14.125448.56740Single point of activity-4.851.22210.997536.9973-11.570130 0 0 030.2349-11.1897-5.77248.651130.2349QC'd by Evotec (US) Inc.
Inactive0-6.24.95490.69662-9.596940 0 0 1-6.1109-7.58075.9101-1.5457-6.1109QC'd by Evotec (US) Inc.
Inactive0-5.853.1320.9409-21.4577.540 0 0 0-17.5516.6865-16.2327-25.7975-17.551QC'd by ChemBridge
Inactive04-8.9062-10.0321-8.4923-13.3892-8.9062QC'd by Enamine
Inactive0-4.44.95490.62637.867851.418340 0 0 013.962331.042659.781363.080913.9623QC'd by Asinex Ltd.
Inhibitor19.952638.612510Single point of activity-4.72.33320.9982-39.7401-1.1275-30 0 0 0-36.5455-1.9894-0.5229-9.5594-36.5455QC'd by Evotec (US) Inc.
Inactive0-6.24.95490.9465-11.49182240 0 0 0-6.912316.7569-14.5765-13.2401-6.9123QC'd by ChemBridge
Inactive04-15.3605-14.6287-17.6489-22.4317-15.3605QC'd by Evotec (US) Inc.
Inactive0-5.54.50450.9992-8.294-20.163740 0 0 1-21.4275-20.1364-17.9575-8.5783-21.4275QC'd by Evotec (US) Inc.
Inactive04-15.0697-19.7843-18.2327-16.8712-15.0697QC'd by Evotec (US) Inc.
Inactive0-5.53.990.9996-14.5384240 0 0 1-1.55331.9923-1.6259-14.1987-1.5533QC'd by Asinex Ltd.
Inactive0-4.853.92950.92562.5-10.304640 0 0 02.6164-8.1304-12.3372-6.37372.6164QC'd by Evotec (US) Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:gene 4 small orf - Marburg virus
External ID: VSVM-OFFLINE
Protocol: Two uL of HEK293 cell suspension are dispensed at 1000 cells/well into solid white 1536-well plates (Grenier) using a Multidrop Combi (Thermo Scientific). After addition of 23 nL compound by a pin tool (Kalypsys), the plate is incubated 1 h at 37 degrees C and then 3 uL of virus 1:100 dilution VSV-MARV is added. After 28 hr, 4 uL of assay reagent is added and the plates are read using a ViewLux (Perkin Elmer). Assays are performed in sub-saturating amounts of virus (MOI <0.5), therefore luciferase signals reflect the amount (titer) of virus able to infect the cells in presence of the compound.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.589 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inactive04.95490.4153-14.5146140 0 0 0 14.685-8.53350.780711.3474-12.51224.685QC'd by "Microsource"
Activator12.589329.27050Single point of activity-4.94.95490.9612311.729530 0 0 0 030.9001-1.47541.01665.62436.608330.9001QC'd by "Microsource"
Activator8.912565.96990Partial curve; partial efficacy-5.050.60.947860.7629-5.2072.20 0 0 0 046.0767-2.32250.745918.756422.519446.0767QC'd by "Microsource"
Inactive04.95490.3508-5.42411240 0 0 0 02.8246.9985-6.3081-17.4367-1.02662.824QC'd by "Microsource"
Inactive04.0950.8518-20.6942-4.843241 0 0 0 0-16.9639-25.916-5.286-19.6983-24.7451-16.9639QC'd by "Microsource"
Inactive04.95490.8518-16.29641.540 0 0 0 14.12061.8961-0.6171-21.497-11.42484.1206QC'd by "Microsource"
Activator2.238783.66590Partial curve; partial efficacy; poor fit-5.650.50.880654.0974-29.56852.40 0 0 0 044.3794-19.3312-4.132918.849613.579244.3794QC'd by "Microsource"
Inhibitor12.589381.174742Partial curve; high efficacy-4.94.0950.9407-88.2352-7.0605-2.10 0 0 0 0-88.059-2.11412.5457-21.0606-24.383-88.059QC'd by "Microsource"
Inactive00.80.97540.51840 0 0 0 00.168615.59399.55235.23893.39690.1686QC'd by "Microsource"
Inactive04.95490.51614-11.192240 0 0 0 08.92332.0681-9.5798-21.4101-15.0678.9233QC'd by "Microsource"
Inhibitor10111.457810Partial curve; high efficacy; poor fit-54.0950.8557-88.020423.4373-2.30 0 0 0 0-86.9630.137116.114955.0816-24.8092-86.963QC'd by "Microsource"
Inhibitor12.5893111.860910Single point of activity-4.91.39870.9539-66.693445.1675-30 0 0 0 0-51.905634.889558.259132.6243.3045-51.9056QC'd by "Microsource"
Inactive049.450123.472150.1914-0.877627.49679.4501QC'd by "Microsource"
Inactive03.62720.9908-9.607722.540 0 0 0 0-9.256421.990720.604224.22328.6092-9.2564QC'd by "Microsource"
Activator0Single point of activity4.95490.354725.2512530 0 0 0 115.41425.71766.534243.23167.091915.4142QC'd by "Microsource"
Inactive04.95490.6074718.540 0 0 0 011.651512.589721.593821.22094.311811.6515QC'd by "Microsource"
Activator2.238752.78950Partial curve; partial efficacy-5.652.25260.961344.2358-8.55372.20 0 0 0 1-9.4264-2.4981-13.18211.959142.1127-9.4264QC'd by "Microsource"
Inactive04.95490.942281.190940 0 0 0 11.53164.67291.2372-2.34124.44781.5316QC'd by "Microsource"
Inhibitor35.481355.762210Single point of activity-4.454.95490.7876-42.791512.9707-30 0 0 0 0-30.683914.51513.87134.773829.0235-30.6839QC'd by "Microsource"
Inhibitor35.481349.231710Single point of activity-4.454.44950.7066-51.9324-2.7008-30 0 0 0 0-40.193-17.989111.8148-5.59920.7455-40.193QC'd by "Microsource"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: VSVL-OFFLINE
Protocol: For screening, 1000 cells in 2 ul/well were dispensed into white solid 1536-well plates (Greiner) using a solenoid-based dispenser. Following transfer of 23nl compound or DMSO vehicle by a pin tool, 3 ul/well of VSV-LV was added. The plates were centrifuged 1 min at 1000 RPM and then incubated 16 hr at 37 C and 5% CO2. After addition of 4 ul/well SteadyLite (PerkinElmer) detection reagent, the plates were incubated 10 min at ambient temperature and luminescence was measured on a ViewLux (Perkin Elmer) plate reader.

Keywords: NIH Roadmap, MLPCN, MLI, MLSMR, qHTS, NCGC, Lassa virus, luciferase, cell assay, infection
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.587 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inhibitor25.118946.394520Partial curve; partial efficacy-4.62.25260.9287-51.2557-4.8612-2.20 0 0 0 0-41.1028-5.7868-8.9838-1.9677-26.4188-41.1028QC'd by "BIOMOL"
Inactive03.51170.943510-4.56740 0 0 0 1-5.6299-3.6518-3.5753-4.22256.795-5.6299QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.937611-2.769540 0 0 0 1-2.8045-1.4193-3.1412-1.90487.584-2.8045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.76251-16.740 0 0 0-0.288-12.255.019-2.495-0.288QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.83354.5-7.094640 0 0 03.0138-4.24556.66523.43423.0138QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9930.5-16.289540 0 0 0 1-17.2531-11.90790.45770.74590.1472-17.2531QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.989-13.9862-8.196440 0 0 0-13.7385-8.6044-8.0804-9.4725-13.7385QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.8435-11.2843440 0 0 0 0-11.90363.48785.23930.52915.9839-11.9036QC'd by "Prestwick Chemical; Inc."
Inactive00.80.72410.6-14.699940 0 0 0 1-12.1307-11.4165-6.1179-8.0206-2.8333-12.1307QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.86521-19.704140 0 0 0 0-4.2947-18.0867-15.93714.83952.1157-4.2947QC'd by "Prestwick Chemical; Inc."
Inhibitor14.125442.146510Single point of activity-4.854.95490.8997-40.14652-30 0 0 0 0-41.8192-2.3935.1804-2.52484.6867-41.8192QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.6566-10.2454040 0 0 0 0-10.2045-4.5492-0.09894.6103-5.6017-10.2045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.52793-11.352240 0 0 01.078-15.7102-2.9932-14.95471.078QC'd by "Prestwick Chemical; Inc."
Inactive01.69240.91230.5-10.14740 0 0 00.4297-9.2892-3.9336-3.15660.4297QC'd by "Prestwick Chemical; Inc."
Inactive02.40640.78868-4.302940 0 0 0 05.7256-1.9822-4.4191-3.81758.01425.7256QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9975.5-12.07640 0 0 1-6.5693-12.5633-7.49474.9219-6.5693QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9232-18.4489-2.283740 0 0 0-16.2075-1.3456-4.9534-0.2364-16.2075QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.94812-17.564340 0 0 0 1-13.5121-12.97033.62471.45070.7522-13.5121QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.5725-10.21937.540 0 0 0 0-12.75555.8917.5423-18.51610.6587-12.7555QC'd by "Prestwick Chemical; Inc."
Inhibitor31.6228100.706940Partial curve; high efficacy-4.53.57220.9933-104.0783-3.3715-2.10 0 0 0 0-83.39610.3188-7.6251-4.9588-20.5702-83.3961QC'd by "BIOMOL"